This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
SUPS 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
SUO 2017
SUO 2017
Testicular Cancer
Kidney Cancer
Penile Cancer
Bladder Cancer
Prostate Cancer
SUO 2017 Kidney Cancer
Viewing 1-20 of 35 articles
SUO 2017: Identifying The Rate And Risks Of Chronic Kidney Disease Development After Cytoreductive Nephrectomy
SUO 2017: Hospital Volume and Short-Term Outcomes after Cytoreductive Nephrectomy
SUO 2017: Cytoreductive Nephrectomy In Patients With Metastatic Renal Cell Carcinoma And Tumor Thrombus – Trends And Effect On Overall Survival
SUO 2017: Perioperative Outcomes of Aspirin Use in Partial Nephrectomy
SUO 2017: Renal Medullary Carcinoma and Collecting Duct Carcinoma of the Kidney
SUO 2017: Validation of The Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer
SUO 2017: Keynote-564: Phase 3, Double-blind, Placebo-controlled Trial Of Pembrolizumab As Adjuvant Treatment For Renal Cell Carcinoma
SUO 2017: Sarcomatoid Differentiation in Renal Cell Carcinoma: Does Stage Make A Meaningful Difference On Survival?
SUO 2017: Should Partial Nephrectomy Be Considered Elective In Stage 2 Chronic Kidney Disease? Propensity Score Matched Analysis Of Functional And Survival Outcomes After Radical And Partial Nephrectomy
SUO 2017: Multiplex Partial Nephrectomy In A Solitary Kidney: The NCI Experience With Partial Nephrectomy For Three or More Tumors in Comparison To Standard Partial Nephrectomy In A Solitary Kidney
SUO 2017: Determinants Of Active Surveillance In Patients With Small Renal Masses
SUO 2017: Small Renal Masses and New Guidelines in Management
SUO 2017: Ablative Technologies for Kidney Masses
SUO 2017: Safe And Effective Partial Nephrectomy Is Feasible In Appropriately Selected Patients With Complex (Renal Nephrometry Score 10-12) Renal Tumors: A Multi-institutional Analysis
SUO 2017: Point - Counterpoint: IVC Thrombectomy for Level 2 Tumor Thrombus Versus a Robotic Approach
SUO 2017: The Evolving Management of Advanced Renal Cell Carcinoma
SUO 2017: Point - Counterpoint: IVC Thrombectomy for Level 2 Tumor Thrombus Versus an Open Approach
SUO 2017: Point - Counterpoint: IVC Thrombectomy for Level 2 Tumor Thrombus Versus an Open Approach
SUO 2017: Management of Recurrent Disease in the Current Era of Kidney Cancer Management
SUO 2017: Results on Active Surveillance for Von Hippel-Lindau-Related Renal Tumors Using Size-Based Risk Stratification
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free